Research - Sarepta Therapeutics (SRPT) is presenting at the JPMorgan Healthcare Conference right now, and released the first figures from the launch of Exondys 51. 250 patients … Continue Reading
Premium: Read NowResearch - Revance Therapeutics (RVNC) just doesn’t stop. After hours on Thursday the company issued a 2017 update. Though we note nothing critical here, the company now … Continue Reading
Premium: Read NowResearch - A recording of last night’s webinar is available for your leisurely viewing this holiday weekend. Last night Mr. King focused primarily on January and early … Continue Reading
Premium: Read NowResearch - Bluebird bio (BLUE) posted the first human results for its anti-BCMA CAR-T candidate bb2121 last evening. This is a novel indication for CAR-T products, and … Continue Reading
Premium: Read NowResearch - Happy thanksgiving! A recording of our November Healthcare Huddle is now available. In it, Mr. King focuses on a handful of trade-able year-end binary events … Continue Reading
Premium: Read NowResearch - Reminder: Our Healthcare Huddle is next Wednesday, Nov 23, at 5:00 ET. We understand that this may conflict with holiday celebrations, so we’ll have a … Continue Reading
Premium: Read NowResearch - For a refresher, Cascadian develops tucatinib (ONT-380), an EGFR-avoiding HER2 inhibitor in mid-stage development for metastatic HER2-positive breast cancer. After two open-label studies in late-stage mBC, a shake-up in the executive suite, and a recent financing, CASC has moved forward with the 180-patient phase 2 HER2CLIMB study, hoping to pivot this study to registration status (with input from the FDA) by the end of the year.
Premium: Read Now
